NBSE News and Press, NeuBase Therapeutics Inc. From 05/12/22

Investigational New Drug (IND)-enabling studies continue to generate promising data that support further development of the company’s lead myotonic dystrophy type 1 (DM1) candidate; new preclinical data to be presented at the American Society of Gene and Cell Therapy (ASGCT) 25th...

PITTSBURGH and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicine...

The CFO trading anomaly is well documented to show abnormal returns among the most knowledgeable insiders. Leveraging the SEC Form 4 database shows there has not been a $1 million CFO share purchase in over 40 days and only 3 so far into 2022. "CFOs utilize more (superior) informa...

A single intravenous dose of NeuBase’s Myotonic Dystrophy Type 1 (DM1) development candidate, NT-0231.F, potently rescue s splicing, restore s chloride channel (Clcn1) function, and durably reverse s myotonia in the HSA LR model...

PITTSBURGH and CAMBRIDGE, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines,...

PITTSBURGH and CAMBRIDGE, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, ...

David Einhorn's 13F stock portfolio value increased from $1.49B to $1.75B this quarter. Greenlight increased Capri Holdings, ODP Group, Livanova, & Victoria’s Secret while reducing Twitter, Concentrix, & EchoStar. They also added Global Payments while dropping AerCap an...

NeuBase Therapeutics press release (NASDAQ:NBSE): FQ1 GAAP EPS of -$0.24. As of December 31, 2021, the Company had cash and cash equivalents of ~$47.3M, compared with ~$52.9M as of September 30, 2021. NeuBase estimates its current cash and cash equivalents are sufficient to fund currently pla...

Investigational New Drug (IND)-enabling studies for the myotonic dystrophy type 1 (DM1) program development candidate continue as planned; invited to present new rodent pharmacokinetic (PK) and bioavailability data in an oral presentation at an upcoming scientific meeting; expects to su...

PITTSBURGH and CAMBRIDGE, Mass., Jan. 10, 2022 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) ("NeuBase" or the "Company"), a biotechnology platform company Drugging the Genome™ to address disease at the base level using a new class of precision genetic medicines, ...